Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals Inc. (ACAD)
:ACAD
RESEARCH TOOLSreports
ACAD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.15 - $26.56
Previous CloseN/A
Volume443.16K
Average Volume (3M)1.82M
Market Cap
$3.38B
Enterprise Value$2.04B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)26.3
Beta1.24
Next Earnings
Mar 26, 2025EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.77
Shares Outstanding166,391,890
10 Day Avg. Volume1,823,499
30 Day Avg. Volume1,819,033
Standard Deviation0.14
R-Squared0.02
Alpha-0.00631
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.52
Price to Cash Flow (P/CF)12.90
P/FCF Ratio13.00
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.00
Enterprise Value/Ebitda16.72
Forecast
1Y Price Target
$25.70Price Target Upside26.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe company submitted the EU marketing authorization for Daybue and expects potential EU approval, which could expand its market reach.
Revenue GrowthAcadia provided first-time 2025 revenues guidance of more than $1B, suggesting potential upside to consensus revenue expectation.
Strategic InvestmentAcadia Pharmaceuticals is paying $28MM upfront for an exclusive worldwide license for SAN711, indicating a strong commitment to this strategic move.
Bears Say
Sales ExpectationsThere is caution on Daybue peak sales and a scarcity of significant near-term catalysts aside from a court decision.
Sales GuidanceExpectations for Daybue are low due to multiple downward guidance revisions throughout 2024.
Sales TargetsExpectations for Daybue sales are low, and meeting the 4Q24 consensus sales forecast may be sufficient, indicating achievable targets.
---
Ownership Overview
24.05% Insiders
15.15% Mutual Funds
0.31% Other Institutional Investors
37.31% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACAD FAQ
What was ACADIA Pharmaceuticals Inc.’s price range in the past 12 months?
ACADIA Pharmaceuticals Inc. lowest stock price was $14.15 and its highest was $26.56 in the past 12 months.
What is ACADIA Pharmaceuticals Inc.’s market cap?
ACADIA Pharmaceuticals Inc.’s market cap is $3.38B.
When is ACADIA Pharmaceuticals Inc.’s upcoming earnings report date?
ACADIA Pharmaceuticals Inc.’s upcoming earnings report date is Mar 26, 2025 which is in 33 days.
How were ACADIA Pharmaceuticals Inc.’s earnings last quarter?
ACADIA Pharmaceuticals Inc. released its earnings results on Nov 06, 2024. The company reported $0.2 earnings per share for the quarter, beating the consensus estimate of $0.138 by $0.062.
Is ACADIA Pharmaceuticals Inc. overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals Inc.’s price is currently Undervalued.
Does ACADIA Pharmaceuticals Inc. pay dividends?
ACADIA Pharmaceuticals Inc. does not currently pay dividends.
What is ACADIA Pharmaceuticals Inc.’s EPS estimate?
ACADIA Pharmaceuticals Inc.’s EPS estimate is 0.22.
How many shares outstanding does ACADIA Pharmaceuticals Inc. have?
ACADIA Pharmaceuticals Inc. has 166,391,890 shares outstanding.
What happened to ACADIA Pharmaceuticals Inc.’s price movement after its last earnings report?
ACADIA Pharmaceuticals Inc. reported an EPS of $0.2 in its last earnings report, beating expectations of $0.138. Following the earnings report the stock price went up 8.93%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in ACAD
---
ACADIA Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.70 (26.66% Upside)
$25.70 (26.66% Upside)
Blogger Sentiment
Bullish
ACAD Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 132.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-18.35%
12-Months-Change
Fundamentals
Return on Equity
27.36%
Trailing 12-Months
Asset Growth
54.44%
Trailing 12-Months
Company Description
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
---
ACAD Company Deck
---
ACAD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong sales growth, particularly for Daybue and NUPLAZID, and promising pipeline developments. However, challenges with patient discontinuation, increased expenses, and delayed impact from marketing campaigns were noted. The overall sentiment reflects a positive outlook with some operational challenges.Read More>---
ACAD Stock 12 Month Forecast
Average Price Target
$25.70
▲(26.66% Upside)
Technical Analysis
Neurocrine
―
Prothena
―
Intra-Cellular Therapies
―
SAGE Therapeutics
―
Axsome Therapeutics
―
Best Analysts Covering ACAD
1 Year
1 Year Success Rate
16/27 ratings generated profit
1 Year Average Return
+8.04%
reiterated a buy rating 15 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 59.26% of your transactions generating a profit, with an average return of +8.04% per trade.
---